TrialReader


A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease

NCT03102632 — Not applicable, Completed, 10 participants, The Rogosin Institute

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT03102632
StatusCompleted
PhaseNot applicable
Study typeInterventional; non randomized, sequential, masking: single, treatment
Enrollment10 (Actual)
SponsorThe Rogosin Institute (Other); collaborators: Weill Medical College of Cornell University
ConditionsAutosomal Dominant Polycystic Kidney
InterventionsHigh Water Intake (Other)
Datesstart 2017-06-01, primary completion 2021-12-31, completion 2021-12-31, first posted 2017-04-06, last updated 2023-10-19
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Autosomal Dominant Polycystic Kidney All trials of High Water Intake

-Summary

Patients affected by Autosomal Dominant Polycystic Kidney Disease (ADPKD) need a safe and effective long-term treatment regimen. Unfortunately, there are still no disease-specific treatment for ADPKD approved in the US. A rational step towards identifying such agents is to test therapies that have a proven safety profile with mechanisms of action that can counter the disease progression.

The purpose of this study is to investigate whether drinking increased amounts of water (water loading) might slow down polycystic kidney growth or kidney function decline. Water loading can cause the suppression of a pathway that causes fluid buildup and cyst growth. High water intake has been safely used in the clinical setting, such as in the case of kidney stone therapy. New York State tap water is widely available and safe, making it highly cost-effective as well.

Expand all sections  ·  Collapse all

+Detailed description

The study will involve 11 visits to the study site over 19 months. Participants will need to follow specific dietary and fluid recommendations. There will be physical examinations and medical history assessments at each visit. Testing will include undergoing magnetic resonance imaging (MRI), blood and urine tests. Study participants will be compensated for their time. Detailed study procedures will be reviewed upon contact with the study team.

+Arms and interventions

ArmTypeInterventionsDescription
Usual Water IntakeNo interventionFor the first 6 months of the study, the participants will continue their usual water intake.
High Water IntakeExperimentalOther: High Water IntakeAfter a 6 month period of usual water intake, a high water intake daily amount will be prescribed for 1 year.
  • High Water Intake (Other): After 6 months of usual, unchanged diet and fluid intake, participants will be asked to increase the daily fluid intake based on the principal investigator's prescription. The actual amount of extra water prescribed will depend on the results of the participant's 24 hour urine test.

+Outcome measures

Primary outcomes

  • Change in total kidney volume, as measured from magnetic resonance imaging [18 months]: Total kidney volumes will be measured before and after the period of high water intake. Kidney volume growth with high water intake will be compared to baseline kidney volume growth.

Secondary outcomes

  • Kidney function change [18 months]: Blood creatinine levels will be measured and compared before and after the high water intake period.
  • Change in urine and blood markers of response to high water intake [18 months.]: Blood and urine biomarkers of response to high water intake will be measured before and after the period of high water intake.

+Eligibility

Sex: All, ages: 18 Years to 65 Years

Inclusion Criteria:

* pre-existing diagnosis of Autosomal Dominant Polycystic Kidney Disease
* estimated glomerular filtration rate of 40 ml/min or greater
* urine osmolality > 400 mOsm/L

Exclusion Criteria:

* estimated glomerular filtration rate less than 40 ml/min
* low blood sodium levels
* syndrome of inappropriate diuretic hormone
* use of thiazide diuretics or selective serotonin reuptake inhibitors (SSRIs)
* use of tolvaptan, another vasopressin receptor antagonist, vasopressin agonists or dDAVP
* contraindications to magnetic resonance imaging (MRI) (pacemakers, defibrillators, implanted electronic devices, metallic foreign body)

+Locations (1)

FacilityCityCountryStatus
The Rogosin InstituteNew York, New YorkUnited States

+Publications

  • Results publication: Dev H, Zhu C, Barash I, Blumenfeld JD, He X, RoyChoudhury A, Wu A, Prince MR. Feasibility of Water Therapy for Slowing Autosomal Dominant Polycystic Kidney Disease Progression. Kidney360. 2024 May 1;5(5):698-706. doi: 10.34067/KID.0000000000000428. Epub 2024 Apr 1. PMID 38556640

+Investigators

  • Martin Prince, MD, Principal investigator, Weill Medical College of Cornell University

My Notes